World Without Disease QuickFire Challenge
Watch the video
World Without Disease QuickFire Challenge

World Without Disease QuickFire Challenge

Challenge ended

$ 500,000 + Optional residency at JLABS

Consumer Health
Medical Devices


Image paragraph

Maryland-based Glyscend, Inc., led by Ashish Nimgaonkar, M.D., Co-founder and CEO, is developing transformative therapies for metabolic diseases (such as type 2 diabetes and obesity) by reducing the concept of bariatric (gastric bypass) surgery into a pill. While type 2 diabetes has traditionally been treated with oral and injectable drugs, these therapies compound over a patient’s lifetime causing weight gain and potentially leading to greater insulin resistance. Bariatric surgery has been shown to have a profound beneficial effect, not only on obesity but also on type 2 diabetes independent of weight loss. Based on the insights from these surgeries, Glyscend is developing the first orally administered intestinal barrier which mimics the intestinal bypass portion of bariatric surgery, thus providing the therapeutic benefits of this surgery in a pill form.

Image paragraph

California-based Neurotrack, led by Elli Kaplan, CEO, is on a mission to transform the diagnosis and prevention of memory loss and related diseases like Alzheimer’s. The company’s product is the Imprint™ Check-Up, a five-minute test that uses eye-tracking technology to assess cognitive decline before symptoms appear. The early diagnosis of memory loss is critical for prevention of cognitive decline and this test is the only tool that can predict memory loss before it starts. In addition, Neurotrack offers a Cognitive Health Program that provides users with tools and advice to make lifestyle changes scientifically proven to reduce the risk of cognitive decline and diseases like Alzheimer’s.

Read More

Read about how innovators are transforming the way illnesses are treated in the most forward-thinking way possible through this challenge: here

Image paragraph

RMIT University’s Micro/Nanomedical Research Center, led by Leslie Yeo, Ph.D., has developed core technology consisting of a portable handheld personalized nebulization platform that enables the aerosolization of drugs for their delivery via inhalation to the lungs. The technology not only offers needle-free administration and the opportunity for systemic delivery of both small and large molecule therapeutics, but also the opportunity for local targeting directly to the lungs, which makes it very attractive for targeting lung diseases, including lung cancer, which is the specific area that represents a critical unmet medical need.

The Challenge

At Johnson & Johnson Innovation and Janssen Research & Development, our goal is to improve the health and wellness of people around the world. To that end, we have a passionate and engaged workforce across our consumer, medical device and pharmaceutical units who are interested in finding and deploying comprehensive, end to end, integrated solutions which take into account the world in which we live today. Johnson & Johnson Innovation and Janssen Research & Development are bringing together the consumer, medical device and pharmaceutical sectors to award $1.5M to the person or team(s) who submits the best idea, technology, or solution that will address a critical health need for the world's population.